RE:RE:RE:RE:RE:RE:How do we determine fair market cap from a licensing deal?
Good grief Moneymouth, why don't you spend the weekend catching up on the last 4 years of posts. People like Biotek, MustangS and myself are not bitter. We are simply tired, no, exhausted by idiots that just fell off the turnip truck trying to engage in discussions without having a fffing clue about the science and the critical value drivers, the MOST critical being immune protection tech. Without, a solid immune protection tech to pair with the pouch, its usage is strictly limited to implantation of a patient's own cells - that pretty much limits the use to thyroid, possibly parathyroid, and the hemacure tech. No pharmaceutical company is going to ink a deal based on the entire diabetes market unless SVA has immune tech. There certainly won't be a buyout without it.